Log in to save to my catalogue

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—...

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1639988738

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

About this item

Full title

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Publisher

United States: Mosby, Inc

Journal title

The American heart journal, 2014-07, Vol.168 (1), p.16-22.e1

Language

English

Formats

Publication information

Publisher

United States: Mosby, Inc

More information

Scope and Contents

Contents

Rationale In patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (pPCI), the use of dual antiplatelet therapy is essential to prevent atherothrombotic complications. Therefore, patients are treated with acetylsalicylic acid and clopidogrel, prasugrel, or ticagrelor. Clopidogrel, ho...

Alternative Titles

Full title

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1639988738

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1639988738

Other Identifiers

ISSN

0002-8703

E-ISSN

1097-6744

DOI

10.1016/j.ahj.2014.03.006

How to access this item